Liquidia (NASDAQ:LQDA) CEO Roger Jeffs Sells 25,000 Shares of Stock

Liquidia Corporation (NASDAQ:LQDAGet Free Report) CEO Roger Jeffs sold 25,000 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $56.29, for a total transaction of $1,407,250.00. Following the completion of the sale, the chief executive officer owned 1,248,095 shares of the company’s stock, valued at $70,255,267.55. The trade was a 1.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roger Jeffs also recently made the following trade(s):

  • On Friday, May 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $57.04, for a total transaction of $1,426,000.00.
  • On Monday, May 11th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $41.50, for a total transaction of $1,037,500.00.
  • On Thursday, May 7th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $42.09, for a total transaction of $1,052,250.00.
  • On Tuesday, May 5th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $40.10, for a total transaction of $1,002,500.00.
  • On Friday, April 17th, Roger Jeffs sold 18,839 shares of Liquidia stock. The shares were sold at an average price of $40.60, for a total transaction of $764,863.40.
  • On Wednesday, April 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.14, for a total transaction of $1,003,500.00.
  • On Tuesday, April 14th, Roger Jeffs sold 3,300 shares of Liquidia stock. The stock was sold at an average price of $40.00, for a total transaction of $132,000.00.
  • On Monday, April 13th, Roger Jeffs sold 32,744 shares of Liquidia stock. The stock was sold at an average price of $38.37, for a total transaction of $1,256,387.28.
  • On Friday, April 10th, Roger Jeffs sold 21,433 shares of Liquidia stock. The stock was sold at an average price of $40.12, for a total transaction of $859,891.96.
  • On Thursday, April 9th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.12, for a total transaction of $1,003,000.00.

Liquidia Stock Down 4.0%

Shares of NASDAQ:LQDA opened at $56.93 on Friday. Liquidia Corporation has a one year low of $11.85 and a one year high of $59.75. The company has a 50 day moving average of $39.70 and a 200-day moving average of $35.94. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 1.84. The stock has a market cap of $5.06 billion, a price-to-earnings ratio of 406.67 and a beta of 0.41.

Liquidia (NASDAQ:LQDAGet Free Report) last issued its quarterly earnings results on Monday, May 11th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The company had revenue of $132.87 million during the quarter, compared to analysts’ expectations of $119.44 million. The company’s quarterly revenue was up 4187.1% on a year-over-year basis. On average, sell-side analysts forecast that Liquidia Corporation will post 2.97 earnings per share for the current year.

Liquidia News Roundup

Here are the key news stories impacting Liquidia this week:

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Covestor Ltd lifted its stake in Liquidia by 41.9% in the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after buying an additional 359 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in Liquidia by 7.2% in the fourth quarter. PNC Financial Services Group Inc. now owns 6,304 shares of the company’s stock valued at $217,000 after buying an additional 422 shares in the last quarter. Northwestern Mutual Wealth Management Co. bought a new position in Liquidia in the fourth quarter valued at approximately $25,000. ProShare Advisors LLC lifted its stake in Liquidia by 7.1% in the fourth quarter. ProShare Advisors LLC now owns 11,756 shares of the company’s stock valued at $405,000 after buying an additional 775 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its stake in Liquidia by 1.4% in the third quarter. Alliancebernstein L.P. now owns 67,050 shares of the company’s stock valued at $1,525,000 after buying an additional 900 shares in the last quarter. Institutional investors own 64.54% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on LQDA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a research report on Tuesday, April 21st. Lifesci Capital raised shares of Liquidia to a “strong-buy” rating in a research note on Thursday, March 5th. Zacks Research raised shares of Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. BTIG Research lifted their price objective on shares of Liquidia from $50.00 to $59.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $60.00 price objective on shares of Liquidia in a research note on Monday. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $49.33.

Get Our Latest Stock Report on Liquidia

About Liquidia

(Get Free Report)

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).

See Also

Insider Buying and Selling by Quarter for Liquidia (NASDAQ:LQDA)

Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.